about
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapyBTS statement on malignant mesothelioma in the UK, 2007.Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human TumorsReview of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesotheliomaScreening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.Functional and mechanistic roles of the human proton-coupled folate transporter transmembrane domain 6-7 linker.Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase.The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this diseaseChemotherapy in non-small cell lung cancer: opportunities for advancement.Pemetrexed-induced radiation recall dermatitis in a patient with lung adenocarcinoma: case report and literature review.Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma.microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
P2860
Q27853125-0A7DEC0A-2778-465A-A044-7F373FBD0B4BQ28534042-7C5844CA-1D70-47EF-B361-208256363404Q30478994-A05E71D8-7435-4899-9186-BF96337DD3C3Q33379936-0487755B-FE8E-4C1D-AA03-62847343E464Q35828644-2882FC57-041D-4C56-BF6A-86C1E8F19838Q36394044-34E6A040-17DB-4E33-A66A-D801F1321A82Q36467564-6B607A31-8ACB-4EC1-8F64-8A944F9FB966Q36822893-598776F0-312A-4C70-9CAF-E595B6AADAEBQ37290519-FB7AB30E-4B08-426E-AC9A-A454DA738538Q37546123-9C7D5048-5711-40B6-8BA8-74AD869239B6Q37587969-DAB558C8-D271-4F85-AFB4-597578E6FBE1Q37663377-DD660446-D671-4168-841A-FB126FAC24B2Q37686318-6E168263-BAAE-44BD-9056-85081481A76AQ38849044-5BAEBC27-6626-4D3E-B186-7B9315CDDB05Q39114430-D4760830-7C6E-4B88-BEAB-5F30C66A6F8EQ42131424-B4EBDD43-2BCF-46F2-9A66-E72E555068FAQ42412951-EA7BBA9A-8D27-42BA-A03A-6B8A0EEF6F4FQ56976088-88BF598C-29DC-4D26-8C5E-430497F74CCA
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pemetrexed in malignant pleural mesothelioma.
@ast
Pemetrexed in malignant pleural mesothelioma.
@en
type
label
Pemetrexed in malignant pleural mesothelioma.
@ast
Pemetrexed in malignant pleural mesothelioma.
@en
prefLabel
Pemetrexed in malignant pleural mesothelioma.
@ast
Pemetrexed in malignant pleural mesothelioma.
@en
P2093
P1476
Pemetrexed in malignant pleural mesothelioma
@en
P2093
Atiqur Rahman
Brian P Booth
Cheng Yi Liang
David E Morse
Doo Y Lee Ham
Jogarao V S Gobburu
John R Johnson
Maitreyee Hazarika
Patricia Garvey
P304
P407
P577
2005-02-01T00:00:00Z